Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review.

J NeurolSep 7, 2026 (epub)
Clinical ResearchNeurologyRadiology (Diagnostic)Open access

Federico Garrou, Lucia Leva, Gian Mauro Sacchetti et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the use of synaptic vesicle glycoprotein 2A (SV2A) PET imaging in assessing presynaptic integrity in parkinsonian α-synucleinopathies, including Parkinson's disease (PD), Parkinson's disease dementia/dementia with Lewy bodies (PDD/DLB), and multiple system atrophy (MSA). The review included 17 reports, highlighting reduced SV2A binding in the substantia nigra in PD and broader cortical abnormalities in PDD/DLB.

Key findings

  • In PD, reduced SV2A binding was most commonly observed in the substantia nigra.
  • PDD/DLB showed broader cortical abnormalities with a link to cognitive performance.
  • MSA exhibited a distinct infratentorial and cerebellar SV2A binding pattern.

Why it matters

Understanding presynaptic dysfunction through SV2A PET imaging may enhance the biological characterization of α-synucleinopathies, potentially leading to improved diagnostic and therapeutic strategies in these conditions.

What to keep in mind

The review notes limitations such as small cohort sizes, methodological heterogeneity, and limited longitudinal evidence.

Source

PubMed · PMID 42704496Free full text on PubMed Central

Published in J Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.